-
Picato Skin Cancer Risk Investigation By European Drug Regulator Prompts Sales Suspension In Europe
January 2020 News Report: FDA “is gathering data and information to investigate the safety concern related to Picato” (Posted by Tom Lamb at DrugInjuryWatch.com) UPDATE: The UK’s Medicines and Health products Regulatory…
-
Acute Renal Failure With Uloric Reported Almost 6 Times More Frequently Compared To Some Other Gout Drugs
Uloric-Related Acute Kidney Injury: Researchers Find A Significantly Higher Reporting Odds Ratio In Women Compared To Men (Posted by Tom Lamb at DrugInjuryWatch.com) Uloric (febuxostat) is a popular urate-lowering therapy (ULT) used…
-
Belviq Cancer Risk Warning Alert Issued To Patients And Doctors In January 2020 FDA Drug Safety Communication
Recent Clinical Trial Findings Suggest Use Of The Weight-Loss Medicine Belviq Increased Risk Of Cancers (Posted by Tom Lamb at DrugInjuryWatch.com) UPDATE: "FDA requests the withdrawal of the weight-loss drug Belviq, Belviq…
-
Are Zantac NDMA Levels Increased By Heat Exposures During Shipping And Storage?
This Theory Would Explain Why NDMA Was Not Found To Be A Problem At Zantac Manufacturing Sites (Posted by Tom Lamb at DrugInjuryWatch.com) The fact that Zantac contains NDMA (nitrosamine impurity called…
-
Gilenya Birth Defects Warnings Issued By Drug Safety Regulators In Canada And Europe — But Not By FDA In The US
Gilenya Increased Risk of Major Congenital Malformations Such As Renal / Kidney And Musculoskeletal Abnormalities, Atrial Septal Defects (Posted by Tom Lamb at DrugInjuryWatch.com) On December 19, 2019 Health Canada issued a…
-
Hemophilia Drug Hemlibra: Adverse Events Reports And Patient Deaths Raise Some Concerns
November 2019 NEJM Letter Points Out Possible Public Health Issue For Hemlibra Used By Hemophilia A Patients (Posted by Tom Lamb at DrugInjuryWatch.com) We recently learned about drug safety issues involving Hemlibra…
